<table id="ID153" width="90%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 15. Summary of Drug Interactions With Lamotrigine </caption>
<col span="1" width="45%"></col>
<col span="1" width="20%"></col>
<col span="1" width="25%"></col>
<tbody>
<tr>
<td>Drug<br/>
</td>
<td>Drug Plasma<br/>Concentration With<br/>Adjunctive<br/>Lamotrigine<sup>a</sup>
<br/>
</td>
<td>Lamotrigine Plasma<br/>Concentration With<br/>Adjunctive Drugs<sup>b</sup>
<br/>
</td>
</tr>
<tr>
<td>Oral contraceptives<br/>(e.g.,ethinylestradiol/levonorgestrel)<sup>c</sup>
<br/>
</td>
<td>↔<sup>d</sup>
<br/>
</td>
<td>↓<br/>
</td>
</tr>
<tr>
<td>Bupropion <br/>
</td>
<td>Not assessed<br/>
</td>
<td>↔<br/>
</td>
</tr>
<tr>
<td>Carbamazepine (CBZ) <br/>
</td>
<td>↔<br/>
</td>
<td>↓<br/>
</td>
</tr>
<tr>
<td>CBZ epoxidee <br/>
</td>
<td>?<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Felbamate <br/>
</td>
<td>Not assessed<br/>
</td>
<td>↔<br/>
</td>
</tr>
<tr>
<td>Gabapentin <br/>
</td>
<td>Not assessed<br/>
</td>
<td>↔<br/>
</td>
</tr>
<tr>
<td>Levetiracetam <br/>
</td>
<td>↔<br/>
</td>
<td>↔<br/>
</td>
</tr>
<tr>
<td>Lithium<br/>
</td>
<td>↔<br/>
</td>
<td>Not assessed<br/>
</td>
</tr>
<tr>
<td>Olanzapine <br/>
</td>
<td>↔<br/>
</td>
<td>↔<sup>f</sup>
<br/>
</td>
</tr>
<tr>
<td>Oxcarbazepine <br/>
</td>
<td>↔<br/>
</td>
<td>↔<br/>
</td>
</tr>
<tr>
<td>10-monohydroxy oxcarbazepine metabolite<sup>g</sup>
<br/>
</td>
<td>↔<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Phenobarbital/primidone <br/>
</td>
<td>↔<br/>
</td>
<td>↓<br/>
</td>
</tr>
<tr>
<td>Phenytoin (PHT) <br/>
</td>
<td>↔<br/>
</td>
<td>↓<br/>
</td>
</tr>
<tr>
<td>Pregabalin <br/>
</td>
<td>↔<br/>
</td>
<td>↔<br/>
</td>
</tr>
<tr>
<td>Rifampin<br/>
</td>
<td>Not assessed<br/>
</td>
<td>↓<br/>
</td>
</tr>
<tr>
<td>Topiramate<br/>
</td>
<td>↔<sup>h</sup>
<br/>
</td>
<td>↔<br/>
</td>
</tr>
<tr>
<td>Valproate<br/>
</td>
<td>↓<br/>
</td>
<td>↑<br/>
</td>
</tr>
<tr>
<td>Valproate + PHT and/or CBZ <br/>
</td>
<td>Not assessed<br/>
</td>
<td>↔<br/>
</td>
</tr>
<tr>
<td>Zonisamide<br/>
</td>
<td>Not assessed<br/>
</td>
<td>↔<br/>
</td>
</tr>
<tr>
<td>
<paragraph></paragraph>
<paragraph>
<sup>a</sup> From adjunctive clinical trials and volunteer studies.<br/>
</paragraph>
<paragraph>
<sup>b</sup>Net effects were estimated by comparing the mean clearance values obtained in adjunctive clinical trials and volunteer studies. <br/>
</paragraph>
<paragraph>
<sup>c</sup>The effect of other hormonal contraceptive preparations or hormone replacement therapy on the pharmacokinetics of lamotrigine has not been systematically evaluated in clinical trials, although the effect may be similar to that seen with the ethinylestradiol/levonorgestrel combinations.<br/>
</paragraph>
<paragraph>
<sup>d</sup>Modest decrease in levonorgestrel <br/>
</paragraph>
<paragraph>
<sup>e</sup>Not administered, but an active metabolite of carbamazepine.<br/>
</paragraph>
<paragraph>
<sup>f</sup>Slight decrease, not expected to be clinically relevant.<br/>
</paragraph>
<paragraph>
<sup>g</sup>Not administered, but an active metabolite of oxcarbazepine. <br/>
</paragraph>
<paragraph>
<sup>h</sup>Slight increase, not expected to be clinically relevant.<br/>
</paragraph>
<paragraph>↔ = No significant effect.<br/>
</paragraph>
<paragraph>? = Conflicting data.<br/>
</paragraph>
</td>
</tr>
</tbody>
</table>